Therefore, it appears that Sod2- and Cat-MSC-based cell therapies prevent non-alcoholic fatty infiltration in the liver (NAFLD), independent of weight loss. This evidence concerns the gene SOD2 and metabolic dysfunction-associated steatotic liver disease.